ST104P, an anti-angiogenic agent
Patent 7709538 Issued on May 4, 2010. Estimated Expiration Date: 
July 14, 2028. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
July 14, 2028. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod of treating herpes simplex virus infection Macrocyclic anti-viral compound and method Method of treating viral infections with aryl macrocyclic compounds Antithrombotic treatment with calix(n)arene compounds Treatment of infection by enveloped virus with calix(N)arene compounds Methods and compositions for inhibition of angiogenesis with EM-138 Patent #: 6469045 InventorsAssigneeApplicationNo. 12172948 filed on 07/14/2008US Classes:514/732Polycyclo ring system (e.g., naphthols, etc.)ExaminersPrimary: Anderson, James DAttorney, Agent or FirmInternational ClassA61K 31/05AbstractThe present invention relates to a method of treating a non-tumor condition or disease associated with angiogenesis in a human or animal comprises administering thereto an effective angiogenesis inhibiting dose of a tetrameric cyclic compound of 4,5-dihydroxynaphthalene-2,7, disulfonic acid linked by methylene bridges in a pharmaceutically acceptable carrier.Other References
Field of SearchPolycyclo ring system (e.g., naphthols, etc.) | |
